AERI News and Press, Aerie Pharmaceuticals Inc. From 07/28/22

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after the market closes Thursday, August 4,...

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced th...

AERI For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Friday's close

Aerie Pharmaceuticals (NASDAQ:AERI) is scheduled to announce Q2 earnings results on Friday, June 10th, after market close. The consensus EPS Estimate is -$0.55 (+33.7% Y/Y) and the consensus Revenue Estimate is $32.53M (+19.6% Y/Y). Over the last 2 years, AERI has beaten EPS estimates 25% of ...

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chief Financial Officer, and Dr. Gary...

Aerie Pharmaceuticals (NASDAQ:AERI) said the first person was dosed in a phase 3 trial of AR-15512 ophthalmic solution to treat the signs and symptoms of dry eye disease. The company added that the phase 3 study, dubbed COMET-2, is the first of three trials in the phase 3 registrational ...

AR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs and symptoms of Dry Eye Disease COMET-2 is the first of three studies in the AR-15512 Phase 3 Program Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical com...

Aerie Pharmaceuticals, Inc. (AERI) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Hans Vitzthum – LifeSci Partners Raj Kannan – Chief Executive Officer Gary Sternberg – Chief Medical Officer Peter Lang – Chief Financial Officer Confere...

Aerie Pharmaceuticals press release (NASDAQ:AERI): Q1 Non-GAAP EPS of -$0.66 misses by $0.01. Revenue of $29.83M (+29.9% Y/Y) misses by $0.07M. Reaffirms 2022 Glaucoma Franchise Guidance of $130 Million to $140 Million. Cash, cash equivalents and total investments were $199.2 million as ...

First Quarter Glaucoma Franchise Net Revenues of $29.8 Million, up 30% over First Quarter 2021 Management Reaffirms 2022 Glaucoma Franchise Guidance of $130 Million to $140 Million First Phase 3 Registrational Trial for AR-15512 On-Track for Enrollment Second Quarter o...